• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Carmat Inc.

Artificial heart developer Carmat could receive up to €17.5M in funding

December 19, 2022 By Sean Whooley

Carmat announced today that the European Council selected it to join its EIC Accelerator program for innovative companies in Europe. The total funding could reach €17.5 million ($18.6 million). Paris-based Carmat develops a total artificial heart. It designed the platform to provide a therapeutic alternative for those suffering from end-stage biventricular heart failure. EIC Accelerator […]

Filed Under: Business/Financial News, Cardiovascular, Featured, Funding Roundup, News Well, Structural Heart Tagged With: artificial hearts, Carmat Inc.

ESC Congress 2019: Biotronik beats Abbott at target lesion failure

September 3, 2019 By Sean Whooley

Biotronik said yesterday that its Orsiro stent tops the Xience stents made by Abbott (NYSE:ABT) when it comes to target lesion failure, according to data from a clinical trial. The randomized, controlled BioSTEMI trial was the first direct comparison between the two drug-eluting stents in patients with acute ST-segment elevation myocardial infarction (STEMI). Biotronik announced […]

Filed Under: Cardiovascular, Catheters, Clinical Trials, Drug-Eluting Stents, Hospital Care, Implants, News Well, Replacement Heart Valves, Stent Grafts, Stents, Surgical Tagged With: Abiomed, atrial fibrillation, Biosense Webster, Biotronik, CABG, Carmat Inc., CellAegis Devices, European Society of Cardiology (ESC), Johnson and Johnson

Fujifilm Sonosite taps Ueda as chair, CEO | Personnel Moves – August 9, 2018

August 9, 2018 By Fink Densford

Fujifilm‘s (TSE:4901) SonoSite subsidiary said earlier this week it appointed Fujifilm vet and current Fujifilm Medical Systems USA and Fujifilm New Development USA prez Takaaki Ueda as its new chair and CEO. Previously, Ueda has also served as Fujifilm global endoscopy systems division GM, the company said. Ueda will replace the departing Masayuki Higuchi who […]

Filed Under: Business/Financial News Tagged With: Biolase, Carmat Inc., Entellus Medical Inc., Fujifilm, Haemonetics, Johnson and Johnson, neurologics, orthoconsulting, Personnel Moves, PositiveID Corp., SonoSite, Tactile Systems Technology

Carmat updates on artificial heart pivotal trial, plans U.S. feasibility study

April 5, 2018 By Fink Densford

Carmat (EPA:ALCAR) today announced updates on its bioprosthetic artificial heart pivotal trial in Europe and said it has submitted files to the FDA seeking an early feasibility trial in the US. The Paris-based company said it has received the regulatory go-ahead to launch its European pivotal trial, looking to implant its bioprosthetic artificial heart in 20 patients […]

Filed Under: Cardiac Implants, Cardiovascular, Clinical Trials Tagged With: Carmat Inc.

Carmat gains on French approval to resume artificial heart trial

May 3, 2017 By Brad Perriello

Carmat (EPA:ALCAR) shares are up today after the company said French regulators approved the resumption of a clinical trial for its artificial heart. France’s national device & drug agency, the Agence Nationale de Sécurité du Médicament, said late yesterday that “Carmat has provided the elements allowing for the resumption of the trial, meeting satisfactory conditions of safety and […]

Filed Under: Structural Heart, Wall Street Beat Tagged With: Artificial Organs, Carmat Inc.

Carmat rescinds bid to resume artificial heart trial

February 7, 2017 By Brad Perriello

Carmat (FRA:CXT) said yesterday that it won’t seek to resume implantations of its artificial heart after all, after French regulators suspended a clinical trial last fall after the 5th death in the study. France’s national drug agency, ANSM, suspended the the trial in December 2016 after the patient died. Yesterday Carmat said the patient’s death was […]

Filed Under: Clinical Trials, Structural Heart, Wall Street Beat Tagged With: Carmat Inc.

France’s drugs agency freezes Carmat implants after 5th death

November 30, 2016 By Fink Densford

France’s national drugs agency said today it is ordering artificial heart maker Carmat (FRA:CXT) to freeze implantation of its devices after the death of a 5th patient last month. The company distanced itself from the death, with chief exec Stephanie Piat stating that the artificial heart was not involved and that the last 3 implantations of the […]

Filed Under: Cardiac Implants, Cardiovascular, Regulatory/Compliance, Structural Heart Tagged With: Carmat Inc.

Carmat shares gain on pivotal trial launch

August 30, 2016 By Brad Perriello

French artificial heart maker Carmat (FRA:CXT) said yesterday that it launched a pivotal trial of its bioprosthetic artificial heart, hoping to use the data to win CE Mark approval in the European Union. The news sent CXT shares up 6.5% to $41.18 (€36.92) apiece today in late-day trading in Frankfurt. Carmat’s shares are off 9.8% so far this year, valuing […]

Filed Under: Cardiovascular, Clinical Trials, Wall Street Beat Tagged With: Carmat Inc.

ESC Congress 2015: St. Jude, HeartFlow tout FFR-guided PCI

September 4, 2015 By Fink Densford

The European Society of Cardiology Congress conference wrapped up this week in London. Here’s a roundup of news from the overseas meeting of interventional cardiologists, dominated by data on fractional flow reserve technology. FFR: St. Jude touts 5 year data showing long-term benefits St. Jude Medical (NYSE:STJ) released 5-year data from a trial comparing the use […]

Filed Under: Cardiac Implants, Cardiovascular, Clinical Trials, Imaging, Surgical, Ultrasound Tagged With: Carmat Inc., European Society of Cardiology (ESC), HeartFlow, Mitralign Inc., Philips, stjudemedical

BSX aims for double-digit earnings growth | Medtech Wall Street news for the week of May 4, 2015

May 7, 2015 By MassDevice Contributors Network Leave a Comment

Boston Scientific aims for double-digit earnings growth

May 1, 2015 by Brad Perriello

Filed Under: News Well, Wall Street Beat Tagged With: Boston Scientific, Carmat Inc., Cruzar Medsystems, Euronext, Kaleidoscope Medical, Pavilion Medical Innovations, Pavmed, Profound Medical Inc., Saphena Medical, Vortex Medical

Carmat: No problem with artificial heart fundamentals despite death

May 6, 2015 By MassDevice Contributors Network Leave a Comment

Carmat: No problem with artificial heart fundamentals despite death

Filed Under: News Well, Structural Heart Tagged With: Artificial Organs, Carmat Inc., Clinical Trials

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy